#acr19 @rheumnow Great debate Dr Saag rebuttal PRO anabolic 1st line rationale for GIO: - Dr Humphrey herself wrote in 2014 and 2018 that teriparatide can be considered as 1st line for GIO https://t.co/GjMrs0YYdj

For persistent arthritis after checkpoint inhibitor cessation, DMARDs don’t seem to blunt tumor response. Increasing issue given the number of patients on combo therapy at risk of arthritis persistence post-ICI cessation. Congratulations @cappelliMD &Dr Braaten!! #ACR19 @RheumNow https://t.co/C3N13D3Dqm https://t.co/H66bnMGGkL

• Laura Cappelli on Twitter: "So proud of Tawnie Braaten for her hard work i…

Which new therapeutic agent in late stage development are you most excited about using in the future? #ACR19 @RheumNow

@rheumnow abs1329 Pooled safety data FINCH1-3 Ph3 trials on Filgotinib showed favorable safety profile FIL mono & in combination w/cDMARDs: incidences of MACE 0.2% for FIL, 0.3%adalimumab (ADA), and 0.5% PBO/csDMARD. Incidences of DVT/PE < 0.1% for FIL, 0% ADA& 0.3% PBO/csDMARD https://t.co/NhC6cWplGu

#acr19 @rheumnow Great debate Rebuttal from Dr Humphrey NO-anabolic 1st line rationale for GIO “While Teri can be considered in certain pts, you should consider bisphos: efficacy and costs —slow and steady win the race”

Abstr#1808: Those who had been treated with immunosuppressive therapy for their inflammatory arthritis have no apparent impact on tumour response. This has been shown in previous studies. #ACR19 @RheumNow

#ACR19 @rheumnow ABS1590 3 RCTs show blockage of TNFα & IL-12/23 associated w/significant improvement in depressive symptoms in PSA pts. GO-REVEAL depression ⬇️ 31.2 to 19.5% w/golimumab; PSUMIT1 36.2 to 20.3% & PSUMIT2 37.2 to 21.2% ⬇️ w/UST. minimal change w/PBO in all 3 trials

Why is the placebo response so high in this tildrakizumab study? #ACR19 @RheumNow https://t.co/H8462OP4jI

Abstr#1808: Hopkins Arthritis Center. IA due to ICIs. IA persisted by 6 mo (20/41-48.8%). Pts tx with combo cancer tx more likely to have persistent IA. Pts w/ >2 other irAEs had more persistent IA. Pts w/ persisting arthritis tend to have better tumour response. #ACR19 @RheumNow

This clarion work on understanding the spectrum of relapsing polychondritis ⭐️⭐️⭐️⭐️⭐️ Highly Recommend @RheumNow @HealioRheum @HRheuminations @CCalabreseDO @RulaHajjAliMD #ACR19 https://t.co/9YfZ7YyQQh

• David Liew on Twitter: &quot;Relapsing polychondritis (RP) has always struck me…

#acr19 @rheumnow Great debate Dr Humphrey NO-anabolic rationale for GIO: the data! Compared to bisph: -Teri is less effective at higher GC dose - Teri and D-mab don’t protect against wrist GC https://t.co/TrNV3PtS8q

#ACR19 @rheumnow abs1759 1-y prospective, monocentric, DB, PBO-cont stdy MTX (10mg/wk) vs PBO in erosive hand OA demonstrates no improvement in VAS pain score with MTX. at the same time MTX significantly ⬇️progression of joint damage vs PBO & seems to facilitate bone remodeling

My hero @philseo who edits @ACRheum ‘s “The Rheumatologist” publication is talking about chondritis, something that also ambushed me #ACR19 @RheumNow https://t.co/LNlFsuHSOc

@RheumNow #ACR19 the list is much longer than one would think https://t.co/pRlgMIWmVF

• Juan Ovalles, MD, PhD on Twitter: &quot;Immunosuppressive medications 💊 and bio…

Dirk suggesting that at this time, as long as active IBD excluded, relatively reassuring low rates of new onset IBD with IL17a inhibition #ACR19 @rheumnow 4M064 https://t.co/R1eAEObR5P